Neurelis Revenue and Competitors

Location

$206.1M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Neurelis's estimated annual revenue is currently $46M per year.(i)
  • Neurelis's estimated revenue per employee is $251,250
  • Neurelis's total funding is $206.1M.

Employee Data

  • Neurelis has 183 Employees.(i)
  • Neurelis grew their employee count by 24% last year.

Neurelis's People

NameTitleEmail/Phone
1
CEO and Co-founderReveal Email/Phone
2
Sr VP, Regulatory Affairs & Quality AssuranceReveal Email/Phone
3
COO & CFOReveal Email/Phone
4
VP Marketing and OperationsReveal Email/Phone
5
VP, Commercial OperationsReveal Email/Phone
6
VP Regulatory AffairsReveal Email/Phone
7
SVP - Strategic InitiativesReveal Email/Phone
8
SVP Corporate DevelopmentReveal Email/Phone
9
VP Human ResourcesReveal Email/Phone
10
Senior Director Scientific OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Neurelis?

Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders. See our community guidelines: https://bit.ly/2HqkNGM

keywords:N/A

$206.1M

Total Funding

183

Number of Employees

$46M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neurelis News

2022-04-17 - NEURELIS EXPANDS INTELLECTUAL PROPERTY ESTATE ...

NEURELIS EXPANDS INTELLECTUAL PROPERTY ESTATE FOR VALTOCO®, A PATIENT-CENTRIC NASAL SPRAY FOR ACUTE TREATMENT OF EPISODES OF FREQUENT...

2022-03-30 - NEURELIS ANNOUNCES THREE POSTER ...

Neurelis, Inc., is a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of...

2022-03-30 - AbbVie, Sage and MT Pharma Anchor Weekend Highlights at ...

Neurelis is slated to present three abstracts at the meeting regarding its completed safety study of Valtoco for the treatment of episodes...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6M183-22%$480M
#2
$33.2M183-8%N/A
#3
$32.4M18410%N/A
#4
$30.5M18510%N/A
#5
$54.9M18524%N/A